搜索
>產品 > 專用于檢測Anti-CD20 (Rituximab) CAR的高特異性抗體

專用于檢測Anti-CD20 (Rituximab) CAR的高特異性抗體

抗體特性經Flow Cytometry驗證并免費提供Protocol

背景
CD20因其在B淋巴細胞發育階段的表達特點被選定為治療B細胞淋巴瘤和白血病的重要靶點之一,也是CAR-T研究領域的熱門靶點。Rituximab是1997年FDA批準的全球第一個靶向CD20用于治療B細胞非霍奇金淋巴瘤的單克隆抗體,是迄今商業化最成功的CD20單抗藥物。根據2018年中檢院頒布的《CAR-T細胞治療產品質量控制檢測研究及非臨床研究考慮要點》,CAR轉染陽性率的檢測應采用流式細胞法,推薦使用具有更好專屬性的針對抗原結合部位的抗原蛋白或抗獨特型抗體進行檢測。
在實際檢測中,抗獨特型抗體(anti-idiotypic antibody)相對抗原來說具有更高的靈敏度和更好的特異性,是檢測CAR表達更為理想的工具。ACROBiosystems開發的Anti-Rituximab Monoclonal Antibodies能夠特異性的識別Rituximab的抗原識別位點,具有特異性強、靈敏度高的特點,經充分驗證可適用于Flow Cytometry (FCM)方法檢測Anti-CD20 (Rituximab) CAR的表達,ACRO可免費提供經驗證的Protocol。
產品列表
Molecule Cat. No. Species Source Product Description
Rituximab RIB-Y35 Mouse Hybridoma Anti-Rituximab Antibodies
產品特點
適用于FCM法檢測Anti-CD20 (Rituximab) CAR的表達
Evaluation of Anti-CD20 (Rituximab) Expression by FCM
2×105 Anti-CD20 (Rituximab)-CAR 293 cells were first stained with anti-rituximab antibody (mouse IgG1, Cat. No. RIB-Y35) and followed by incubation with PE-labeled anti-mouse IgG1 antibody. PE-labeled anti-mouse IgG1 antibody was used as a negative control.

Protocol

能夠特異性的識別Rituximab的抗原識別位點
Neutralizing activity measured by FCM

Flow Cytometry analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of anti-rituximab antibodies (Cat. No. RIB-Y35). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.013 μg/ml.

Protocol

High affinity determined by SPR

Anti-rituximab antibodies (mouse IgG1, Cat. No. RIB-Y35) captured on CM5 chip via anti-mouse antibodies surface, can bind rituximab with an affinity constant of 0.03 nM.

国产视频app Protocol

*如果您希望ACRO開發更多類型的Anti-Rituximab Antibodies產品, 請 點擊提議
*如果您希望ACRO補充更多Anti-Rituximab Antibodies產品的實驗設計和應用數據,請 點擊咨詢

消息提示

国产视频app請輸入您的聯系方式,再點擊提交!

確定